✦ LIBER ✦

Immunoadjuvant action of liposomes: comparison with other adjuvants

✍ Scribed by Gregory Gregoriadis; Christina Panagiotidi

Publisher: Elsevier Science
Year: 1989
Tongue: English
Weight: 298 KB
Volume: 20
Category: Article
ISSN: 0165-2478
DOI: 10.1016/0165-2478(89)90086-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A comparison of forgers with other crimi

A comparison of forgers with other criminals

✍ Arnold Leunes; Larry Christensen 📂 Article 📅 1975 🏛 John Wiley and Sons 🌐 English ⚖ 255 KB

Comparison of nacre with other ceramic c

Comparison of nacre with other ceramic composites

✍ A. P. Jackson; J. F. V. Vincent; R. M. Turner 📂 Article 📅 1990 🏛 Springer 🌐 English ⚖ 556 KB

Stereochemical comparison of nebivolol w

Stereochemical comparison of nebivolol with other β-blockers

✍ Carsten D. Siebert; André Hänsicke; Thomas Nagel 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB

Comparison of computerised tomography wi

Comparison of computerised tomography with other neuroradiological methods

✍ G. H. Boulay; E.-W. Radue 📂 Article 📅 1978 🏛 Springer 🌐 English ⚖ 263 KB

Comparison of Computerized Tomography with Other Neuroradiological Examination Methods Comparison of Computerised Tomography with Other Neuroradiological Methods

S10.13 Binding specificity of bacterial

S10.13 Binding specificity of bacterial adhesins fromNeisseria subflavastrains and other bacteria to glycolipids incorporated into liposomes: Comparison with TLC binding patterns

✍ M. Abul-Milh; J. Ångström; H. Dezfoolian; K. -A. Karlsson 📂 Article 📅 1993 🏛 Springer US 🌐 English ⚖ 249 KB

Mechanism of action of certolizumab pego

Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti-tumor necrosis factor α agents

✍ Andrew Nesbitt; Gianluca Fossati; Marianne Bergin; Paul Stephens; Sue Stephens; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 329 KB

Background: Inhibitors of tumor necrosis factor ␣ (TNF␣) have demonstrated significant efficacy in chronic inflammatory diseases, including Crohn's disease (CD). To further elucidate the mechanisms of action of these agents, we compared the anti-TNF␣ agents certolizumab pegol, infliximab, adalimumab